Using yeast to discover new enzyme inhibitors
Leveraging the yeast surface as a platform for inhibitor discovery
['FUNDING_OTHER'] · TUFTS UNIVERSITY MEDFORD · NIH-11062455
This study is exploring new ways to make antibodies work better by adding special building blocks to them, which could lead to better treatments for patients by finding stronger ways to block harmful enzymes.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TUFTS UNIVERSITY MEDFORD (nih funded) |
| Locations | 1 site (Boston, UNITED STATES) |
| Trial ID | NIH-11062455 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the capabilities of antibodies by chemically modifying them to create unique hybrids that can inhibit enzymes more effectively. By manipulating the genetic code in yeast, the team aims to incorporate noncanonical amino acids into antibodies, allowing for the discovery of new binding proteins with improved functionalities. The approach involves high-throughput screening to identify potent enzyme inhibitors that traditional methods may not uncover. Patients may benefit from advancements in targeted therapies that arise from these innovative binding proteins.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with conditions that could be treated by novel enzyme inhibitors, such as certain cancers or autoimmune diseases.
Not a fit: Patients with conditions not related to enzyme activity or those who do not respond to enzyme inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective enzyme inhibitors that improve treatment options for various diseases.
How similar studies have performed: Previous research has shown success in using similar genetic code manipulation techniques to enhance protein functionalities, indicating a promising avenue for this approach.
Where this research is happening
Boston, UNITED STATES
- TUFTS UNIVERSITY MEDFORD — Boston, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VAN DEVENTER, JAMES ALLEN — TUFTS UNIVERSITY MEDFORD
- Study coordinator: VAN DEVENTER, JAMES ALLEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.